SEHK:512Pharmaceuticals
Grand Pharmaceutical Group (SEHK:512) Margin Squeeze Reinforces Bearish Earnings Narratives
Grand Pharmaceutical Group (SEHK:512) has opened FY 2025 with first half revenue of HK$6.1b and basic EPS of HK$0.33, setting the tone for how its earnings story is evolving after a year of shifting margins. Over recent periods the company has seen revenue move from HK$6.0b in 1H 2024 to HK$5.6b in 2H 2024 and then to HK$6.1b in 1H 2025. Basic EPS tracked HK$0.44, HK$0.26 and HK$0.33 across the same halves, giving investors a clearer view of how the top line and EPS are aligning with a...